Multidrug resistance-associated protein 4 is a determinant of arsenite resistance

Oncology Reports

Volumn 35, Issue 1, 2016, Pages 147-154

  Yuan, Bo ^a,b   Yoshino, Yuta ^b   Fukushima, Hisayo ^a   Markova, Svetlana ^a   Takagi, Norio ^b   Toyoda, Hiroo ^b   Kroetz, Deanna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Arsenite; Cytotoxicity; MRP2; Multidrug resistance; Multidrug resistance associated protein 4

Indexed keywords

ARSENIC TRIOXIDE; CYCLOSPORIN A; GLUTATHIONE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN; VERLUKAST; ABCC4 PROTEIN, HUMAN; ARSENOUS ACID DERIVATIVE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PROPIONIC ACID DERIVATIVE; QUINOLINE DERIVATIVE;

APICAL MEMBRANE; ARTICLE; CANCER CELL LINE; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; HEK293 CELL LINE; METABOLISM;

ARSENITES; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROPIONATES; QUINOLINES;

EID: 84954042047     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4343     Document Type: Article

References (36)

1. Yuan B, Yoshino Y, Kaise T and Toyoda H: Application of arsenic trioxide therapy for patients with leukemia. In: Biological Chemistry of Arsenic, Antimony and Bismuth. Sun H (ed). John Wiley and Sons, Ltd., Chichester, pp263-292, 2011.
2. Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, O'Leary JJ, White RM, Williams GA and Pazdur R: Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6: 4-11, 2001.
3. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
4. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
5. Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, et al: Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol 59: 485-493, 2007.
6. Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H and Ohyashiki K: Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res 34: 403-405, 2010.
7. Yoshino Y, Yuan B, Miyashita SI, Iriyama N, Horikoshi A, Shikino O, Toyoda H and Kaise T: Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 393: 689-697, 2009.
8. Iriyama N, Yoshino Y, Yuan B, Horikoshi A, Hirabayashi Y, Hatta Y, Toyoda H and Takeuchi J: Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. J Hematol oncol 5: 1, 2012.
9. 3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353, 1997.
10. Morjani H and Madoulet C: Immunosuppressors as multidrug resistance reversal agents. Methods Mol Biol 596: 433-446, 2010.
11. Lee TC, Ho IC, Lu WJ and Huang JD: Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J Biol Chem 281: 18401-18407, 2006.
12. Leslie EM, Haimeur A and Waalkes MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 279: 32700-32708, 2004.
13. Bhattacharjee H, Carbrey J, Rosen BP and Mukhopadhyay R: Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun 322: 836-841, 2004.
14. Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz DL and Toyoda H: Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol 257: 198-208, 2011.
15. Iriyama N, Yuan B, Yoshino Y, Hatta Y, Horikoshi A, Aizawa S, Takeuchi J and Toyoda H: Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts. Oncol Rep 29: 2362-2368, 2013.
16. Yuan B, Ohyama K, Bessho T and Toyoda H: Contribution of inducible nitric oxide synthase and cyclooxygenase-2 to apoptosis induction in smooth chorion trophoblast cells of human fetal membrane tissues. Biochem Biophys Res Commun 341: 822-827, 2006.
17. Yuan B, Ohyama K, Bessho T, Uchide N and Toyoda H: Imbalance between RoS production and elimination results in apoptosis induction in primary smooth chorion trophoblast cells prepared from human fetal membrane tissues. Life Sci 82: 623-630, 2008.
18. Yuan B, Ohyama K, Takeichi M and Toyoda H: Direct contribution of inducible nitric oxide synthase expression to apoptosis induction in primary smooth chorion trophoblast cells of human fetal membrane tissues. Int J Biochem Cell Biol 41: 1062-1069, 2009.
19. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, et al: The human multidrug resistance protein 4 (MRP4, ABCC4): Functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 325: 859-868, 2008.
20. Kelly L, Fukushima H, Karchin R, Gow JM, Chinn LW, Pieper U, Segal MR, Kroetz DL and Sali A: Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains. Protein Sci 19: 2110-2121, 2010.
21. Russel FG, Koenderink JB and Masereeuw R: Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29: 200-207, 2008.
22. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H and Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62: 3144-3150, 2002.
23. Tian Q, Zhang J, Chan SY, Tan TM, Duan W, Huang M, Zhu YZ, Chan E, Yu Q, Nie YQ, et al: Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 7: 105-118, 2006.
24. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, Bian JS, et al: Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 22: 1837-1853, 2005.
25. Copsel S, Bruzzone A, May M, Beyrath J, Wargon V, Cany J, Russel FG, Shayo C and Davio C: Multidrug resistance protein 4/ATP binding cassette transporter 4: A new potential therapeutic target for acute myeloid leukemia. Oncotarget 5: 9308-9321, 2014.
26. Oevermann L, Scheitz J, Starke K, Köck K, Kiefer T, Dölken G, Niessen J, Greinacher A, Siegmund W, Zygmunt M, et al: Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer 124: 2303-2311, 2009.
27. Banerjee M, Carew MW, Roggenbeck BA, Whitlock BD, Naranmandura H, Le XC and Leslie EM: A novel pathway for arsenic elimination: Human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII). Mol Pharmacol 86: 168-179, 2014.
28. Lee K, Klein-Szanto AJ and Kruh GD: Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92: 1934-1940, 2000.
29. Lee G and Piquette-Miller M: Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 79: 876-884, 2001.
30. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A and Fridland A: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5: 1048-1051, 1999.
31. Kikuchi H, Yuan B, Yuhara E, Imai M, Furutani R, Fukushima S, Hazama S, Hirobe C, Ohyama K, Takagi N, et al: Involvement of histone H3 phosphorylation via the activation of p38 MAPK pathway and intracellular redox status in cytotoxicity of HL-60 cells induced by Vitex agnus-castus fruit extract. Int J Oncol 45: 843-852, 2014.
32. Carew MW and Leslie EM: Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): Implications for the mutual detoxification of arsenic and selenium. Carcinogenesis 31: 1450-1455, 2010.
33. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS and Lieberman MW: The MRP2/cMoAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275: 33404-33408, 2000.
34. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG, Russel FG, Shayo C and Davio C: Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286: 6979-6988, 2011.
35. Zhao Q, Tao J, Zhu Q, Jia PM, Dou AX, Li X, Cheng F, Waxman S, Chen GQ, Chen SJ, et al: Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 18: 285-292, 2004.
36. Zhu Q, Zhang JW, Zhu HQ, Shen YL, Flexor M, Jia PM, Yu Y, Cai X, Waxman S, Lanotte M, et al: Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99: 1014-1022, 2002.